Gla

PLT Health Solutions menatto™ Vitamin K2 is Verified Non-GMO by the Non-GMO Project

Retrieved on: 
Monday, October 31, 2022
BMD, Elasticity, Marketing, Vitamin, Vitamin K2, Food, Woman, Solution, Gla, GMO, Bacillus subtilis, MK-7, The Non-GMO Project, Vitamin K, Fermentation, Calcium, New product development, PLT, K2, Health, Dietary supplement

MORRISTOWN, N.J., Oct. 31, 2022 /PRNewswire/ -- PLT Health Solutions, Inc. announced that it has received non-GMO verification from the Non-GMO Project company for its menatto™ Vitamin K2 (MK-7) ingredient. The verification covers raw materials, manufacturing processes and logistics. Introduced in the US market by PLT in March of 2022, menatto brand of Vitamin K2 (MK-7) is manufactured by edible oils producer J-Oil Mills (Tokyo, Japan). menatto was developed in 1997, featuring the world's first fermentation technology to manufacture vitamin K2 from the traditional Japanese food natto. Since then, the ingredient has been the subject of ten human clinical trials covering bioavailability, bone health and cardiovascular health.

Key Points: 
  • Premium Vitamin K2 (MK-7) is Clinically Studied, Fully Traceable and Clean Label
    MORRISTOWN, N.J., Oct. 31, 2022 /PRNewswire/ -- PLT Health Solutions, Inc. announced that it has received non-GMO verification from the Non-GMO Project company for its menatto Vitamin K2 (MK-7) ingredient.
  • Introduced in the US market by PLT in March of 2022, menatto brand of Vitamin K2 (MK-7) is manufactured by edible oils producer J-Oil Mills (Tokyo, Japan).
  • menatto was developed in 1997, featuring the world's first fermentation technology to manufacture vitamin K2 from the traditional Japanese food natto.
  • Since then, the ingredient has been the subject of ten human clinical trials covering bioavailability, bone health and cardiovascular health.

PLT Will Market J-Oil Mills' menatto™ Vitamin K2 (MK-7) in North America

Retrieved on: 
Wednesday, March 30, 2022
Vitamin K, Bacillus subtilis, New product development, Fermentation, Gla, Research, Plant, Woman, Health, Philosophy, Food, PLT, BMD, Edible, MK-7, Solution, Phytomenadione, Elasticity, Calcium, Dietary supplement, K2, Vitamin K2

MORRISTOWN, N.J., March 30, 2022 /PRNewswire/ -- PLT Health Solutions, Inc. announced today that it will market menatto brand of Vitamin K2 (MK-7) manufactured by an edible oils producer J-Oil Mills (Tokyo, Japan) in North America for use in consumer products supporting cardiovascular health, bone health, and general health. menatto was developed in 1997, featuring the world's first fermentation technology to manufacture vitamin K2 from the traditional Japanese food natto. Since then, the ingredient has been the subject of ten human clinical trials covering bioavailability, bone health and cardiovascular health. This makes menatto the world's most researched Vitamin K2.

Key Points: 
  • menatto was developed in 1997, featuring the world's first fermentation technology to manufacture vitamin K2 from the traditional Japanese food natto.
  • menatto Vitamin K2 is menaquinone-7 (MK-7) manufactured by J-Oil Mills in the Shizuoka district of Japan.
  • Gold standard studies on menatto Vitamin K2 include:
    A 3-year, randomized, double-blind, placebo-controlled study of post-menopausal women found that supplementing with low-dose menatto Vitamin K2 helped bind calcium to bones, supporting healthy bone mineral density.
  • "PLT Health Solutions has been in the Vitamin K2 business for almost twenty years and was one of the companies that played a key role in building the North American market.

KAPPA BIOSCIENCE ANNOUNCES THE FORMATION OF A BLUE RIBBON SCIENTIFIC AND MEDICAL ADVISORY BOARD

Retrieved on: 
Wednesday, March 2, 2022
Division, Food Science and Technology International, Health, Advisory board, Moses Austin, Board, Molecular Nutrition & Food Research, Diabetes, MGP, Metabolism, Pharmacokinetics, Inflammation, National Science Advisory Board for Biosecurity, NIH, Awareness, Science, University, Calcium, Vitamin K2, Company, Yale University, Associate, VP, Cardiology, Washington University School of Medicine, Professor, Artery, Exercise, Dyslipidemia, MK-7, Kappa, Gla, Texas A&M University, Leadership, Technology, Army Science Board, Quality of life, Doctor of Philosophy, University of California, San Francisco, Epidemiology, Physiology, Cardiovascular disease, Research, Advisory, History of the University of Maryland, College Park, Dietary supplement, Pharmaceutical industry, Management, Marketing, K2, Immunology

OSLO, Norway, March 1, 2022 /PRNewswire/ -- Kappa Bioscience ( www.kappabio.com ), the leading manufacturer of Vitamin K2 under the brand name K2VITAL announced today the formation of a "Blue Ribbon" Scientific and Medical Advisory Board to support and expand the scientific knowledge base for Vitamin K2.

Key Points: 
  • OSLO, Norway, March 1, 2022 /PRNewswire/ -- Kappa Bioscience ( www.kappabio.com ), the leading manufacturer of Vitamin K2 under the brand name K2VITAL announced today the formation of a "Blue Ribbon" Scientific and Medical Advisory Board to support and expand the scientific knowledge base for Vitamin K2.
  • Kappa Bioscience is pleased to announce the current composition of the Advisory Board:
    Dr. John Ivy, the Teresa Lozano Long Endowed Chair Emeritus at the University of Texas at Austin.
  • Dominik Mattern, VP of Marketing, concludes: "Kappa Bioscience has always been a forerunner in the K2 market.
  • Kappa Bioscience is dedicated to developing superior quality health solutions around vitamin K2 to improve the quality of life.